EDP chemotherapy combined with somatostatin analogues and mitotane in the treatment of disseminated adrenocortical carcinoma: a clinical case
- Authors: Magamedova O.R.1, Oganesyan L.V.1,2, Feoktistova P.S.1, Feidorov I.Y.1
-
Affiliations:
- Loginov Moscow Clinical Scientific Center
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 26, No 1 (2024)
- Pages: 118-121
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/258583
- DOI: https://doi.org/10.26442/18151434.2024.1.202643
- ID: 258583
Cite item
Full Text
Abstract
Adrenocortical carcinoma is an orphan disease with an annual incidence of 1–2 cases per 1 million adults. The median overall survival (OS) is only 17 months. Definitive surgery increases the median OS to 28 months. The article presents a clinical case of a patient with hormonally active adrenocortical carcinoma of the right adrenal gland, accompanied by tumor thrombosis of the inferior vena cava extending to the right atrium. Surgery was performed for the thrombus removal. A wrong initial diagnosis led to a delay in adjuvant mitotane therapy. The recurrence of the disease was treated with mitotane and somatostatin analogues, considering the high expression of somatostatin receptors in the tumor. At the second progression, the patient was switched to chemotherapy in the EDP regimen combined with continued therapy with mitotane and octreotide, resulting in long-term control of the disease. The time without progression and OS were 18 and 42 months, respectively.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Olga R. Magamedova
Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: magamedowa.onco@yandex.ru
ORCID iD: 0009-0003-9875-2525
Medical Resident
Russian Federation, MoscowLiana V. Oganesyan
Loginov Moscow Clinical Scientific Center; Russian Medical Academy of Continuous Professional Education
Email: liana15.94@mail.ru
ORCID iD: 0000-0001-7564-7472
Junior researcher, Graduate Student of the department
Russian Federation, Moscow; MoscowPolina S. Feoktistova
Loginov Moscow Clinical Scientific Center
Email: krisman03@gmail.com
ORCID iD: 0000-0002-0340-7119
Cand. Sci. (Med.)
Russian Federation, MoscowIlia Yu. Feidorov
Loginov Moscow Clinical Scientific Center
Email: i.feidorov@mknc.ru
ORCID iD: 0000-0001-8369-5116
Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Sharma E, Dahal S, Sharma P, et al. The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population Based Study. J Clin Med Res. 2018;10(8):636-40.
- Kerkhofs TMA, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579-86.
- Клинические рекомендации – взрослые. AOP. Режим доступа: https://oncology-association.ru/clinical-guidelines. Ссылка активна на 18.06.2023 [Klinicheskiie rekomendatsii – vzroslyie. AOP. Available at: https://oncology-association.ru/clinical-guidelines. Accessed: 18.06.2023 (in Russian)].
- Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476-90.
- Erdogan I, Deutschbein T, Jurowich C, et al. The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2013;98(1):181-91.
- Glenn JA, Else T, Hughes DT, et al. Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery. 2019;165(1):186-95.
- Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. N Engl J Med. 2007;356(23):2372-80.
- Tang Y, Liu Z, Zou Z, et al. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. BioMed Res. 2018;2018:9362108.
- Postlewait LM, Ethun CG, Tran TB, et al. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. J Am Coll Surg. 2016;222(4):480.
- Berruti A, Fassnacht M, Libe R, et al. First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. J Clin Oncol. 2022;40(6_suppl):1-1.
- Fassnacht M, Terzolo M, Allplio B, et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med. 2012;366(23):2189-97.
- Mariniello B, Finco I, Sartorato P, et al. Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells. J Endocrinol Invest. 2011;34(6):e131-e8.
- Grisanti S, Filice A, Basile V, et al. Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors. J Clin Endocrinol Metab. 2020;105(3):dgz091.
- Коломейцева А.А, Делекторская В.В., Орел Н.Ф., и др. Рецепторы соматостатина как потенциальная терапевтическая мишень в лечении распространенного адренокортикального рака. Клинический случай. Сибирский онкологический журнал. 2018;17(2):111-7 [Kolomeytseva AA, Delektorskaya VV, Orel NF, et al. Somatostatin receptors as potentialtherapeutic targets in the treatment of advanced adrenocortical cancer. A case report. Siberian Journal of Oncology. 2018;17(2):111-7 (in Russian)].